Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adherium Ltd. ( (AU:ADR) ) has shared an update.
Adherium Limited has disclosed substantial changes to director George Baran’s direct and indirect holdings following a series of share issues, option exercises, and conversions of convertible notes. Through Trudell Medical Limited and related transactions approved by shareholders in November 2025, Baran’s indirect interest increased to more than 842 million fully paid ordinary shares and a significantly enlarged portfolio of unlisted options, while his convertible notes position was reduced to zero as they were converted into equity. The transactions, largely priced at $0.005 per share or note with free attaching options, consolidate Baran’s equity stake and reinforce insider alignment with Adherium’s capital structure and future performance, effectively increasing long-term exposure for a key strategic director-shareholder.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australian-listed company operating in the medical technology sector, with a focus on digital health solutions related to respiratory care. Its shareholder base includes Trudell Medical Limited, in which director George Baran holds a significant beneficial interest, indicating strategic ties to the broader medical devices and respiratory therapy market.
Technical Sentiment Signal: Sell
Current Market Cap: A$18.39M
See more data about ADR stock on TipRanks’ Stock Analysis page.